This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Beta Atlas: Charting Global Production of Nonconventional β--Emitters for Targeted Radiopharmaceutical Therapy-Part 1.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026 · senior author
Treatment of Human Glioblastoma Multiforme in NRG Mice by Convection-Enhanced Delivery of EGFR-Targeted or Nontargeted Auger Electron-Emitting 197gHg-Labeled Gold Nanoparticles.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
Recycling-compatible electroplating of enriched tin-119 targets for the production of antimony-119 for targeted Auger electron therapy.
EJNMMI radiopharmacy and chemistry · 2026 · senior author
Latest funding
- $596,701
Development of targeted alpha therapy (TAT) radiopharmaceuticals for melanoma treatment using 213Bi, 225Ac, and 227Th labelled alpha melanocyte stimulating hormone (alphaMSH) derivatives
CIHR · 2022 · Co-investigator
- $562,275
Leveraging Trans-Canada Expertise and Resources to Design and Evaluate Novel Auger Electron-Emitting Radioimmunotherapies (RIT) for Metastatic Triple-Negative Breast Cancer (TNBC)
CIHR · 2021 · Nominated PI
73 publications.
Beta Atlas: Charting Global Production of Nonconventional β--Emitters for Targeted Radiopharmaceutical Therapy-Part 1.
Tosato M, Kleynhans J, van de Voorde M, Favaretto C, Harriswangler C, Chaple I, Mastroianni S, Starovoitova V, Hoerres R, Burgoyne A, Korde A, Gestin JF, van der Meulen NP, Asti M, Köster U, Ramogida CF, Radchenko V
Treatment of Human Glioblastoma Multiforme in NRG Mice by Convection-Enhanced Delivery of EGFR-Targeted or Nontargeted Auger Electron-Emitting 197gHg-Labeled Gold Nanoparticles.
Brown MK, Cai Z, Ganga-Sah Y, Alshafai L, Borlase S, Radchenko V, Gao A, Rutka JT, Reilly RM
Recycling-compatible electroplating of enriched tin-119 targets for the production of antimony-119 for targeted Auger electron therapy.
Grundmane A, Ramogida CF, Radchenko V
Panitumumab labeled with Auger electron-emitting 197gHg/197mHg: cytotoxicity on human breast cancer cells and tumour and normal tissue uptake in mice with EGFR-overexpressing breast cancer xenografts.
Chu ACK, Ho F, Chan C, Cai Z, Ganga-Sah Y, Randhawa P, Ramogida CF, Radchenko V, Reilly RM
Modeling the yields of225Ra/225Ac and the resulting225Ac radioisotopic purity from proton irradiation of232Th at 100-800 MeV.
Jang J, Radchenko V, Miao Q, Wada Y, Schaffer P, Hoehr C
Quantitative dual-isotope preclinical SPECT/CT imaging and biodistribution of the mercury-197m/g theranostic pair with [197m/gHg]HgCl2 and a [197m/gHg]Hg-tetrathiol complex as a platform for radiopharmaceutical development.
Randhawa P, Rodríguez-Rodríguez C, Koniar H, Davey PRWJ, Chen S, Radchenko V, Ramogida CF
Theoretical optimal232Th target thicknesses for225Ac production at proton energies of 70-200 MeV.
Jang J, Schaffer P, Radchenko V, Moskven L, Akimitsu N, Wada Y, Hoehr C
Developing ether and alcohol based extraction chromatography resins for purification of antimony-119 in nuclear medicine.
Grundmane A, Dovhyi I, Aburto-Kung L, Happel S, Ramogida CF, Radchenko V
Auger electron-emitting EGFR-targeted and non-targeted [197Hg]Hg-gold nanoparticles for treatment of glioblastoma multiforme (GBM).
Brown MK, Cai Z, Georgiou CJ, Chen S, Ganga-Sah Y, Radchenko V, Rutka JT, Reilly RM
Radiochemistry of cyclen-derived chelators comprising five-membered azaheterocyclic arms with 212Pb2+, 213Bi3+, and 225Ac3.
Hierlmeier I, Randhawa P, McNeil BL, Oliveri E, Maus S, Radchenko V, Rosar F, Ezziddin S, Bartholomä MD
Development of targeted alpha therapy (TAT) radiopharmaceuticals for melanoma treatment using 213Bi, 225Ac, and 227Th labelled alpha melanocyte stimulating hormone (alphaMSH) derivatives
Principal investigators: Yang, Hua; Benard, Francois
Keywords: A-Melanocyte-Stimulating Hormone; Alpha Particle Emitting Radionuclides; Melanocortin 1 Receptor; Melenoma Treatment; Radiochemistry Development; Radiopharmaceutical Development; Targeted Radionuclide Therapy
Leveraging Trans-Canada Expertise and Resources to Design and Evaluate Novel Auger Electron-Emitting Radioimmunotherapies (RIT) for Metastatic Triple-Negative Breast Cancer (TNBC)
Principal investigators: Radchenko, Valery; Reilly, Raymond M
Keywords: Radiopharmaceutical Science
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Chemistry
- Molecular Oncology
- Other
Co-authors at University of British Columbia, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.